Mode
Text Size
Log in / Sign up
Phase 4 N=58 Randomized Single-blind Treatment

Tobacco and Socioeconomic Disadvantage

Tobacco Smoking

Enrolled (actual)
58
Serious AEs
0.0%
Results posted
Nov 2019
Primary outcome: Primary: Self-reported Serious Quit Attempt Measured Via the 'Quitting Preparation and Actions Questionnaire' — 5; 10; 6 Participants — p=<0.05

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Motivational Interviewing (Behavioral); Nicotine Replacement Therapy Sampling (Drug); Referral Only (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Rutgers, The State University of New Jersey
Primary completion
Oct 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Self-reported Serious Quit Attempt Measured Via the 'Quitting Preparation and Actions Questionnaire'
5; 10; 6 <0.05 sig
PRIMARY
Self-reported Treatment Seeking Measured Via the 'Quitting Preparation and Actions Questionnaire'
0; 1; 3 .113
SECONDARY
Self-reported Cigarettes Per Day
13.0; 7.6; 10.3 .032 sig
SECONDARY
Importance, Confidence, & Readiness Questionnaire
4.8; 5.5; 6.5; 7.6; 7.3; 8.1 .227
SECONDARY
Readiness to Quit Ladder
5.7; 6.6; 6.4 .188

Summary

Randomized clinical trial comparing 3 brief interventions designed to increase motivation to quit smoking in socioeconomically disadvantaged smokers.

Eligibility Criteria

Inclusion Criteria

  • Participants must be between the age of 19 and 65
  • Participants must self-report being a daily smoker and provide biochemical verification of smoking status (expired breath carbon monoxide reading >5)
  • Participants must be at socioeconomic disadvantage, defined as receiving services at a New Brunswick, New Jersey based social services agency (i.e., living in New Brunswick Housing Authority-run public housing units or requesting social services from the community social service agency, "Elijah's Promise")
  • Participants must be able to speak and read English.

Exclusion Criteria

  • Participants may not be taking FDA approved smoking cessation or anti-psychotic medications
  • Participants may not reported medical issues of potential concern to nicotine replacement users (e.g., unstable angina pectoris, myocardial infarction, or significant cardiac arrythmia (including atrial fibrillation) in the past 30 days)
  • Participants may not report pending legal issues with potential to result in incarceration.
  • Participants may not be pregnant or nursing, planning on becoming pregnant in the next two months, and must be using effective birth control.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03620708). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search